
Fulvestrant Chemical - Application: Pharmaceutical Industry
Price:
Get Latest Price
Minimum Order Quantity :
1
In Stock
Product Specifications
| Molecular Weight | 606.77 Grams (g) |
| Place of Origin | China |
| Storage | Freezer |
| Molecular Formula | C32H47F5O3S |
| Other Names | ICI 182,780;FULVESTRANT;FULVESTRANT-13C1-D2;FASLODEX;(7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol |
| CAS No | 129453-61-8 |
| Grade | Medicine Grade |
| Usage | Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women; it is given by injection. A 2017 Cochrane review found it is as safe and effective as first line or second line endocrine therapy |
| Purity | 98%min |
| Appearance | white solid |
| Application | Pharmaceutical Industry |
| Form | Solid |
| FOB Port | Shanghai |
| Payment Terms | Letter of Credit (L/C), Paypal, Letter of Credit at Sight (Sight L/C), Telegraphic Transfer (T/T), Others |
| Supply Ability | 1000 Per Week |
| Delivery Time | 10 Days |
| Sample Available | Yes |
| Sample Policy | Contact us for information regarding our sample policy |
| Packaging Details | foil/bag/bottle |
| Main Export Market(s) | Australia, North America, Eastern Europe, Western Europe, Middle East, Africa, Central America, South America, Asia |
Company Details
Focusing on a customer-centric approach, CHEMVON BIOTECHNOLOGY (SHANGHAI) CO. LTD. has a pan-India presence and caters to a huge consumer base throughout the country. Buy Pharmaceutical Chemicals in bulk from CHEMVON BIOTECHNOLOGY (SHANGHAI) CO. LTD. at Trade India quality-assured products.
Business Type
Exporter, Manufacturer, Distributor, Supplier, Trading Company
Employee Count
250
Establishment
2004
Working Days
To
Related Products
More Products From This Seller
Seller Details
Shanghai, Shanghai
CEO
Mr. Peter Dong Wang
Members since
14 Years
Address
Suite B-10, Chuansha Road 6999#, Shanghai, Shanghai, 201203, China
fulvestrant in Shanghai
Report incorrect details






























